New SPRQ-Nx chemistry designed to deliver the most complete view of the genome for less than $300 at scaleMENLO PARK, Calif., Oct. 14, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), developer of the world's most advanced sequencing technologies, today announced innovations to its Revio and Vega platforms designed to lower sequencing costs, add new multiomic capabilities, and expand support for regulated research environments. The advancements center on new SPRQ-Nx sequencing chemistry and consumables, whic ...

Core Insights - PacBio's Special Committee has completed an independent investigation into allegations regarding employment practices and cybersecurity, finding no improper practices or material inaccuracies in disclosures [1][2] Company Overview - PacBio is a leading life science technology company focused on advanced sequencing solutions aimed at resolving genetically complex problems across various research applications, including human germline sequencing and oncology [2] Product Information - PacBio's products are designated for Research Use Only and are not intended for diagnostic procedures [3]